A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A

A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A

Bibliographic Details
Main Authors: M.C. Ozelo, K.J. Pasi, S. Rangarajan, N. Mitchell, W. Lester, E. Symington, B. Madan, M. Laffan, C.B. Russell, M. Li, B. Kim, G.F. Pierce, W.Y. Wong
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920303850

Internet

http://www.sciencedirect.com/science/article/pii/S2531137920303850

Similar Items